3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow MEDI-545: new trials by email Literature Review of MEDI-545 trials Research Report on MEDI-545
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Sifalimumab 200 mg, Sifalimumab 600 mg, Sifalimumab 1,200 mg - Systemic Lupus Erythematosus | Phase 2 | Completed | MedImmune LLC | 834 | 2011-03-31 | 2018-04-19 |
| A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. MEDI-545, MEDI-545 600 - Systemic Lupus Erythematosus | Phase 2 | Completed | AstraZeneca | 30 | 2009-11-25 | 2018-11-19 |
| A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus MEDI-545, Placebo - Lupus Erythematosus, Systemic, Lupus | Phase 2 | Completed | MedImmune LLC | 87 | 2008-07-01 | 2016-08-09 |
Lupus Erythematosus, Systemic (3) · Autoimmune Diseases (1) · Immune System Diseases (1)
MedImmune LLC (2) · AstraZeneca (1)
United States (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Italy (1) · Jamaica (1) · Japan (1) · Mexico (1) · Netherlands (1)
Gabor Illei, MD (1) · Tsutomu Takeuchi (1) · Warren Greth, M.D. (1) · Yoshiya Tanaka (1)